+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology, and Market Forecast-2030

  • ID: 4751848
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 211 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • argenx
  • GeNeuro Pharmaceuticals
  • LFB
  • MedDay Pharmaceuticals
  • Nihon Pharmaceutical
  • Pfizer
  • MORE
‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted CIDP symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2030

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding and Treatment Algorithm:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction). A great deal of evidence, such as the finding of inflammation at the site of the lesion, response to immunomodulatory treatment and possibly the presence of autoantibodies against myelin antigens. The inflammation of the peripheral nervous system damages the myelin sheaths that insulate nerve fibers. CIDP usually spares the nerves that supply muscles of respiration and the autonomic nerves that control the bladder, bowel, and circulation. The disorder sometimes also called chronic relapsing polyneuropathy.

The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. It can occur at any age and in both genders, CIDP is more common in young adults, and men more so than women. This condition is treatable for relatively long periods (months to years) in the majority of patients. CIDP usually presents in the “classical” form as the symmetrical disorder with proximal and distal weakness but also can manifest as a variety of other subtypes that can be multifocal or selectively involve sensory or motor nerve fibers.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosis and Treatment:

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report gives a thorough understanding of CIDP symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides CIDP symptoms of treatment algorithms and treatment guidelines for CIDP symptoms in the US, Europe, and Japan.

The EFNS/PNS diagnostic criteria can address most of the diagnostic pitfalls and able to distinguish the different sub-types. According to EFNS/PNS guidelines, misdiagnosis is common in CIDP, especially in the atypical subtype. Electrophysiologic testing, the sensitivity of which is improved by testing more than 4 nerves, is necessary to confirm the diagnosis. The testing of 3 limbs may improve the diagnostic certainty of electrophysiologic testing. High-resolution ultrasound is a readily available tool that can be used at the bedside. Recent study results have demonstrated the potential utility of measuring abnormal nerve enlargement, both in the brachial plexus and proximal median nerve segments in the arm, with high-resolution ultrasound in the differential diagnosis of CIDP.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology:

The CIDP symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings:

The total diagnosed prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CIDP symptoms epidemiology segmented as the Total prevalence of CIDP, Gender-Specific cases of CIDP, Clinical Subtype specific cases of CIDP, Age-Specific cases of CIDP. The report includes the prevalent scenario of CIDP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology:

The epidemiology segment also provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of CIDP in 7MM countries was estimated to be 44,700 in 2017.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Chapters:

The drug chapter segment of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report encloses the detailed analysis of CIDP marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed Drugs:

Privigen: CSL Behring
Privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment. Privigen is the first and only, ready-to-use, sterile, room-temperature stored, liquid, polyvalent IVIG stabilized with L-proline. The drug acts as an immunostimulant. It is approved in the US, Europe, and Japan for the treatment of CIDP in adults to improve neuromuscular disability and impairment.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Drugs:

GGS-CIDP: Teijin Pharma

GGS-CIDP is an intravenous, freeze-dried sulfonated human normal immunoglobulin which reported to shows high efficacy in restoring the lost muscle strength by its immune regulatory action of inhibiting the inflammation of the peripheral nerves; the drug thus offers promise as a treatment that will restore lost muscle strength. The molecule has completed the Phase III developmental studies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and filed NDA for manufacturing and marketing approval of GGS-CIDP.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook:

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM is expected to change in the study period 2017–2030.

The current therapeutic landscape in the 7MM divided into conventional therapies such as Corticosteroids, Plasma Exchange (PE), and Intravenous immunoglobulin (IVIG) which are also considered as the first line of therapy. In Corticosteroids therapy, mostly Prednisone and Dexamethasone are indicated among them. It induces a therapeutic response after 2 months and maximal improvement is observed after a long period with gradual incremental of dose. It has been in the therapeutic use for CIDP as of the first reporting of cases.

Plasma Exchange (PE) is an invasive therapy that requires well-trained personnel at specialized centers. It demonstrated short-term efficacy in the early days formerly may deteriorate within weeks to months after treatment.

Intravenous immunoglobulin (IVIG) has been used as the first-line therapy for CIDP over the past two decades with established efficacy and recommended to be offered as the long-term treatment. Though, the therapy with IVIG is expensive and time-consuming, and may have limited availability in some circumstances; the patient reported Improvement usually within a few weeks.

Key Findings:

This section includes a glimpse of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM. The market size of CIDP in the seven major markets is expected to be USD 968 million in 2017.

The United States Market Outlook:

This section provides the total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in the United States.

The United States accounts for the highest market size of CIDP in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Even though the IVIG has proven efficacy, the therapies are associated with the high cost and frequent adverse effects.

EU-5 Countries: Market Outlook:

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Currently, used IVIG products are licensed for CIDP either purely nationally or via the MR-procedure in certain EU states or, in one case, centrally in the entire EU. The Tegeline of the LFB has been got approval from the France authorities. The Polyvalent immunoglobulins of the Kedrion Biopharma were approved by the Italian authorities to include in the CIDP treatment regimens. The approval of the SCIG paved the way for patient compliance therapies shortly. Consequently, the market share is expected to increase during the forecast period [2020–2030]

Japan Market Outlook:

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in Japan are also mentioned.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Development Activities:

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) key players involved in developing targeted therapeutics.

Major players include Teijin Pharma, Octapharma, Shire/ Takeda, MedDay Pharmaceuticals, UCB Biopharma, argenx, Momenta Pharmaceuticals, Pfizer and others. GGS-CIDP (Teijin Pharma), NewGam (Octapharm) and HyQvia (Shire/Takeda) are the late-stage immunoglobin therapies.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) emerging therapies.

Reimbursement Scenario in CIDP:

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher takes reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

Commercial insurance companies typically reimburse for IG to treat many diseases regardless of whether they are designated as FDA-approved for IG therapy. Medicare Part B will reimburse IG for most diagnosis codes in the physician office or hospital outpatient setting. Both Typical and Atypical CIDP are covered under the FDA approved (Diagnosis Code - 357.81) condition to get coverage for IG therapy.

KOL - Views

To keep up with current market trends, the publisher takes KOLs and SME’s opinion working in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of CIDP, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
Report Highlights
  • In the coming years, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for CIDP. Launch of emerging therapies will significantly impact the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CIDP
The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Key Strengths:
  • 11 Years Forecast
  • 7MM Coverage
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Assessment:
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What were the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)market Size during the forecast period (2017–2030)?
  • At what CAGR, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the CIDP?
  • What is the historical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CIDP?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the USA, Europe, and Japan?
  • What are the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CIDP?
  • How many therapies are developed by each company for the treatment of CIDP?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of CIDP?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and their status?
  • What are the key designations that have been granted for the emerging therapies for CIDP?
  • What are the global historical and forecasted market of CIDP?
Reasons to buy:
  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • argenx
  • GeNeuro Pharmaceuticals
  • LFB
  • MedDay Pharmaceuticals
  • Nihon Pharmaceutical
  • Pfizer
  • MORE
1. Key Insights

2. Executive summary

3. Methodology

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Overview at a Glance
4.1. Total Market Share (%) Distribution of CIDP in 2017
4.2. Total Market Share (%) Distribution of CIDP in 2030

5. Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview
5.1. Introduction
5.2. Classification
5.3. Clinical Presentation
5.4. CIDP versus Guillain-Barre Syndrome
5.4.1. Disease course
5.5. Disease associations with CIDP
5.6. Pathogenesis of CIDP
5.6.1. FcRN role in the CIDP
5.7. Diagnosis
5.7.1. Diagnostic criteria
5.7.2. Differential diagnosis
5.7.3. AAN electrodiagnostic criteria
5.7.4. Koski et al’s criteria
5.7.5. European Federation of Neurological Societies and the Peripheral Nerve Society

6. Organizations

7. Epidemiology and Patient Population
7.1. Key Findings

8. Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM

9. United States Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalent Population of CIDP in the United States
9.3. Gender-Specific Prevalent Population of CIDP in the United States
9.4. Clinical Subtype based Diagnosed cases of CIDP in the United States
9.5. Age-Specific Prevalent Population of CIDP in the United States

10. EU5 Epidemiology
10.1. Germany Epidemiology
10.1.1. Assumptions and Rationale
10.1.2. Total Prevalent Population of CIDP in Germany
10.1.3. Gender-Specific Prevalent Population of CIDP in Germany
10.1.4. Clinical Subtype based on Diagnosed cases of CIDP in Germany
10.1.5. Age-Specific Prevalent Population of CIDP in Germany
10.2. France Epidemiology
10.2.1. Assumptions and rationale
10.2.2. Total Prevalent Population of CIDP in France
10.2.3. Gender-Specific Prevalent Population of CIDP in France
10.2.4. Clinical Subtype based on Diagnosed cases of CIDP in France
10.2.5. Age-Specific Prevalent Population of CIDP in France
10.3. Italy Epidemiology
10.3.1. Assumptions and Rationale
10.3.2. Total Prevalent Population of CIDP in Italy
10.3.3. Gender-Specific Prevalent Population of CIDP in Italy
10.3.4. Clinical Subtype based on Diagnosed cases of CIDP in Italy
10.3.5. Age-Specific Prevalent Population of CIDP in Italy
10.4. Spain Epidemiology
10.4.1. Assumptions and Rationale
10.4.2. Total Prevalent Population of CIDP in Spain
10.4.3. Gender-Specific Prevalent Population of CIDP in Spain
10.4.4. Clinical Subtype based on Diagnosed cases of CIDP in Spain
10.4.5. Age-Specific Prevalent Population of CIDP in Spain
10.5. United Kingdom Epidemiology
10.5.1. Assumptions and Rationale
10.5.2. Total Prevalent Population of CIDP in the UK
10.5.3. Gender-Specific Prevalent Population of CIDP in the UK
10.5.4. Clinical Subtype based Diagnosed cases of CIDP in the UK
10.5.5. Age-Specific Prevalent Population of CIDP in the UK
10.6. Japan Epidemiology
10.6.1. Assumptions and Rationale
10.6.2. Total Prevalent Population of CIDP in Japan
10.6.3. Gender-Specific Prevalent Population of CIDP in Japan
10.6.4. Clinical Subtype based on Diagnosed cases of CIDP in Japan
10.6.5. Age-Specific Prevalent Population of CIDP in Japan

11. Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.1. Biological Activity of Available Treatments
11.2. EFNS/PNS Guideline on the management of CIDP
11.3. American Academy of Neurology (AAN) – CIDP Evidence-based guidelines
11.4. Treatment of CIDP - Cochrane systematic review

12. Treatment Algorithm

13. Unmet Needs

14. Marketed drugs
14.1. Privigen: CSL Behring
14.1.1. Drug Description
14.1.2. Regulatory Milestones
14.1.3. Other Developmental Activities
14.1.4. Safety and Efficacy
14.1.5. Product Profile
14.2. Hizentra: CSL Behring
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Development Activities
14.2.4. Safety and Efficacy
14.2.5. Product Profile
14.3. Gamunex-C: Grifols/Kedrion Biopharma
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Development Activities
14.3.4. Safety and Efficacy
14.3.5. Product Profile
14.4. Kenketsu Glovenin-I: Nihon Pharmaceutical
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Safety and Efficacy
14.4.4. Product Profile
14.5. Tegeline: LFB
14.5.1. Product Description
14.5.2. Regulatory Milestones
14.5.3. Product Profile

15. Emerging Therapies
15.1. Key Cross Competition
15.2. GGS-CIDP: Teijin Pharma
15.2.1. Drug Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.2.5. Product Profile
15.3. NewGam: OctaPharma
15.3.1. Product Description
15.3.2. Clinical Development
15.3.3. Product Profile
15.4. HyQvia: Shire/ Takeda
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.4.4. Product Profile
15.5. Rozanolixizumab: UCB Biopharma
15.5.1. Product Description
15.5.2. Clinical Development
15.5.3. Safety and Efficacy
15.5.4. Product Profile
15.6. MD-1003: MedDay Pharmaceuticals
15.6.1. Drug Description
15.6.2. Other Developmental Activities
15.6.3. Clinical Development
15.6.4. Product Profile
15.7. Other potential therapies
15.8. I10E: LFB
15.8.1. Drug Description
15.8.2. Other Developmental Activities
15.8.3. Clinical Development
15.8.4. Product Profile
15.9. GNbAC1: GeNeuro Pharmaceuticals
15.9.1. Drug Description
15.9.2. Other Developmental Activities
15.9.3. Clinical Development
15.9.4. Safety and Efficacy
15.9.5. Product Profile
15.10. PF-06755347: Pfizer
15.10.1. Drug Description
15.10.2. Other Developmental Activities
15.10.3. Clinical Development
15.10.4. Product Profile
15.11. Efgartigimod: argenx
15.11.1. Drug Description
15.11.2. Clinical Development
15.11.3. Product Profile
15.12. M254: Momenta Pharmaceuticals
15.12.1. Drug Description
15.12.2. Other Developmental Activities
15.12.3. Product Profile

16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): 7MM Market Analysis
16.1. Key Findings
16.2. Market Size of CIDP in 7MM

17. United States: Market Outlook
17.1. United States Market Size
17.1.1. The total market size of CIDP
17.1.2. Market Size of CIDP by therapy in the US

18. EU-5 countries: Market Outlook
18.1. Germany Market Size
18.1.1. The total market size of CIDP
18.1.2. Market Size of CIDP by Emerging therapy in Germany
18.2. France Market Size
18.2.1. The total market size of CIDP
18.2.2. Market Size of CIDP by Emerging therapy in France
18.3. Italy Market Size
18.3.1. The total market size of CIDP
18.3.2. Market Size of CIDP by Emerging therapy in Italy
18.4. Spain Market Size
18.4.1. The total market size of CIDP
18.4.2. Market Size of CIDP by Emerging therapy in Spain
18.5. United Kingdom Market Size
18.5.1. The total market size of CIDP
18.5.2. Market Size of CIDP by Emerging therapy in the UK

19. Japan Market Outlook
19.1. Japan Market Size
19.1.1. The total market size of CIDP
19.1.2. Market Size of CIDP by Emerging therapy in Japan

20. Market Drivers

21. Market Barriers

22. Case Studies
22.1.1. A Case Report of CIDP presented with unilateral ptosis
22.1.2. A Case Report of Electrophysiological responsiveness to long-term therapy in CIDP

23. Reimbursement policies
23.1. Access and Reimbursement Overview for Current and Future Therapies
23.1.1. Current Therapies
23.1.2. Future Therapies

24. SWOT Analysis

25. KOL Views

26. Appendix
26.1. Report Methodology

27. Publisher Capabilities

28. Disclaimer

29. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CSL Behring
  • Grifols/Kedrion Biopharma
  • Nihon Pharmaceutical
  • LFB
  • Teijin Pharma
  • OctaPharma
  • Shire/ Takeda
  • UCB Biopharma
  • MedDay Pharmaceuticals
  • LFB
  • GeNeuro Pharmaceuticals
  • Pfizer
  • argenx
  • Momenta Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll